Send to

Choose Destination
Semin Intervent Radiol. 2017 Jun;34(2):132-139. doi: 10.1055/s-0037-1601852. Epub 2017 Jun 1.

Making the Case: Intra-arterial Therapy for Less Common Metastases.

Author information

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois.
Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, Illinois.
Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, Illinois.


Intra-arterial therapies have high antitumor activity for both primary and secondary hepatic malignancies. Selective infusions allow increased delivery of cytoreductive therapy to the tumor bed while sparing the normal hepatic parenchyma. These therapies are now often applied in the outpatient setting or with short overnight hospital stays and have a growing role in the treatment of liver-dominant disease from metastatic colorectal cancer and from neuroendocrine tumors. Less commonly, intra-arterial therapies are applied to treat secondary hepatic malignancies from breast cancer, melanoma, pancreatic adenocarcinoma, and soft-tissue sarcomas. The available data are limited and generally retrospective observational cohort series of single institutions. The purpose of this article is to summarize the recent literature on outcomes for intra-arterial therapy in nonsurgical patients. Multi-institutional registries and prospective data are greatly needed, as intra-arterial therapies are increasingly applied in these patients to stop progression of chemorefractory tumors.


chemoembolization; hepatic artery infusion chemotherapy; interventional radiology; liver metastases; radioembolization

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center